LY 2334737
Alternative Names: Gemcitabine prodrug; LY-2334737Latest Information Update: 02 Oct 2021
At a glance
- Originator Eli Lilly and Company
- Class Amides; Antineoplastics
- Mechanism of Action DNA synthesis inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Solid tumours
Most Recent Events
- 18 Sep 2013 Discontinued - Phase-I for Solid tumours in USA (PO)
- 13 Aug 2012 Phase-I development is ongoing in USA
- 18 Oct 2010 Phase-I development is ongoing in USA